Mild Cognitive Impairment – Epidemiology – Middle East Africa
We review the published literature, including online registries and surveys, using a systematic search with a defined date range, for the most representative epidemiological data on MCI.
We summarize the results of our review for the epidemiological estimates of prevalence that are used directly in our forecast model in the “Studies Included” table. How we used these estimates and to which countries they were applied are discussed in the text and summarized in the sources table in the relevant epidemiology population sections. We report the most relevant sources not used and the reason for not using them in the “Studies Excluded” table
Table of contents
- Mild Cognitive Impairment - Epidemiology - Middle East Africa
- Introduction
- Key Findings
- Total Prevalence of Mild Cognitive Impairment per 1,000 Among People Aged 65 or Older in 2020 and 2030
- Total Prevalence of Mild Cognitive Impairment per 1,000 Among People Aged 65 or Older in 2020 and 2030
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Mild Cognitive Impairment over the Next Ten Years
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Mild Cognitive Impairment over the Next Ten Years
- Total Prevalent Cases of Mild Cognitive Impairment by Subtype
- Total Prevalent Cases of Mild Cognitive Impairment by Subtype
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Related Market Assessment Reports
Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
